Genedrive plc (GB:GDR) has released an update.
Genedrive plc, a leader in point-of-care pharmacogenetic testing, has partnered with a major U.S. physician group to conduct clinical trials for FDA approval of its Genedrive MT-RNR1 ID Kit. This revolutionary test aims to prevent antibiotic-induced hearing loss in newborns, which has significant health and economic benefits. The test is particularly relevant for the U.S. market due to its birth rates, litigation costs from antibiotic side effects, and favorable diagnostic testing environment.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
